15.4 The Normal Menstrual Cycle & Anticipatory Guidance

Everything that counts as abnormal bleeding is defined against what counts as normal, so the hypothalamic-pituitary-ovarian axis and the parameters of a normal cycle come first. This section also covers the anticipatory guidance the AMCB blueprint asks for by name: what to tell patients about menarche and adolescent cycles, how to distinguish premenstrual syndrome from premenstrual dysphoric disorder, and how to recognize and prevent menstrual toxic shock syndrome.

---

Normal Menstrual Cycle Neuroendocrinology

A regular menstrual cycle reflects the coordinated, reciprocal feedback loop of the Hypothalamic-Pituitary-Ovarian (HPO) axis acting directly on the uterine endometrium. Normal menstrual parameters in reproductive-age individuals encompass:

• Cycle Frequency: 24 to 38 days (measured from the first day of menses to the first day of the subsequent menses).
• Cycle Regularity: Variation between shortest and longest cycle of ≤7 to 9 days.
• Bleeding Duration: ≤8 days of flow.
• Volume of Blood Loss: Subjectively normal without causing anemia, flooding, or lifestyle disruption (historically quantified as 5 to 80 mL).

Menstrual Cycle Regulatory Cascade
├── Hypothalamus ──> Pulsatile Gonadotropin-Releasing Hormone (GnRH)
│                      │ (Slow pulse frequency favors FSH; rapid favors LH)
│                      ▼
├── Anterior Pituitary ──> Follicle-Stimulating Hormone (FSH) & Luteinizing Hormone (LH)
│                            │
│                            ▼
├── Ovaries (Ovarian Cycle) ──> Folliculogenesis, Ovulation, & Corpus Luteum
│                                 │ (Estradiol & Progesterone secretion)
│                                 ▼
└── Uterine Target (Endometrial Cycle) ──> Proliferative, Secretory, & Menstrual Phases

1. The Ovarian Cycle: Follicular vs. Luteal Phase

• Follicular (Pre-ovulatory) Phase: Initiated on Day 1 of menses. Pulsatile GnRH stimulates the anterior pituitary to secrete FSH, which recruits a cohort of antral follicles. Ovarian granulosa cells aromatize theca-derived androgens into estradiol (E2). As estradiol levels rise, FSH undergoes negative feedback inhibition, selecting a single dominant follicle (Graafian follicle) with the highest density of FSH receptors. The duration of the follicular phase is physiologically variable (typically 10 to 21 days) and accounts for normal menstrual cycle variability.
• Ovulatory Mid-Cycle Surge: When sustained high circulating estradiol levels (>200 pg/mL for >48 hours) are attained by the mature dominant follicle, the feedback mechanism abruptly switches from negative to positive feedback, triggering the massive pituitary LH surge (with a smaller concurrent FSH surge). LH triggers resumption of oocyte meiosis, follicular rupture, and extrusion of the mature ovum approximately 24 to 36 hours after the onset of the surge (or 10 to 12 hours after the LH peak).
• Luteal (Post-ovulatory) Phase: Following ovulation, the collapsed follicle luteinizes into the corpus luteum under the influence of LH. Luteinized granulosa and theca cells produce high concentrations of progesterone along with moderate estradiol. Progesterone exerts potent negative feedback on pituitary LH and FSH. Unlike the follicular phase, the luteal phase has a fixed, invariant lifespan of 14 ± 2 days. If conception and trophoblast hCG production do not occur, the corpus luteum undergoes programmed luteolysis into the fibrous corpus albicans, precipitating an acute withdrawal of progesterone and estradiol.

2. The Endometrial Cycle: Proliferative, Secretory, & Menstrual Phases

• Proliferative Phase (Estrogen-Driven): Paralleling the ovarian follicular phase, rising estradiol induces rapid mitotic activity in the basal endometrial glands and stroma, regenerating the stratum functionalis from the surviving stratum basalis. Glands are initially straight, narrow, and tubular; the endometrial lining thickens from 1–2 mm up to 8–12 mm.
• Secretory Phase (Progesterone-Driven): Paralleling the ovarian luteal phase, post-ovulatory progesterone halts endometrial cellular mitosis and initiates secretory differentiation. Glands become highly tortuous, coiled, and dilated, accumulating glycogen-rich vacuoles. Stromal cells undergo decidualization, and spiral arterioles elongate and coil tightly to supply the vascularized bed in preparation for blastocyst implantation.
• Menstrual Phase (Progesterone Withdrawal): Luteolysis causes a precipitous drop in circulating progesterone and estradiol. Loss of hormonal support triggers intense, spasmodic constriction of the spiral arterioles, producing focal ischemia, hypoxia, and tissue necrosis of the stratum functionalis. Lysosomal enzymes release matrix metalloproteinases (MMPs), digesting the stromal extracellular matrix. Concurrently, local prostaglandins (PGF2α and PGE2) stimulate rhythmic myometrial contractions to expel the necrotic decidual tissue and blood, while platelet plugs and local vasoconstrictors arrest bleeding in the basal vascular beds.

---

Anticipatory Guidance Across the Menstrual Lifespan

Menarche

Menarche occurs at a US median of about 12.4 years, with a normal range of roughly 8 to 15 years. Thelarche (breast budding) precedes it by about 2 to 2.5 years. ACOG treats the menstrual cycle as a vital sign in adolescents: cycles in the first 1 to 2 years after menarche are often anovulatory and irregular, but intervals should still fall within 21 to 45 days and never exceed 90 days. Evaluate no menses by age 15 with normal secondary sexual characteristics, or by age 13 with none.

Counsel adolescents and parents about what is normal (cycle length, flow duration, mittelschmerz, cyclic breast tenderness and mucus changes) and what is not (soaking a pad or tampon hourly, cycles more than 90 days apart, disabling dysmenorrhea that keeps her out of school).

Premenstrual Syndrome and Premenstrual Dysphoric Disorder

Cyclic mood and physical change in the luteal phase is normal; the diagnosis is made by pattern, severity, and impairment — never by a single visit's recall.

• PMS: physical and behavioral symptoms in the luteal phase that resolve within a few days of the onset of menses, with a symptom-free interval in the follicular phase.
• PMDD (DSM-5-TR): at least 5 symptoms in the final week before menses, improving within a few days after onset and minimal in the week after, with at least one core affective symptom — marked lability, irritability or anger, depressed mood, or anxiety and tension — causing significant distress or impairment.
• Diagnosis requires prospective daily ratings across at least 2 cycles (for example the Daily Record of Severity of Problems). Retrospective report misclassifies roughly half of self-diagnosed cases.

Treatment: SSRIs are first-line for PMDD and are unusual among antidepressant indications in that they work within days, which allows either continuous or luteal-phase-only dosing. Continuous combined oral contraception, particularly the drospirenone 3 mg with ethinyl estradiol 20 mcg 24/4 regimen, is FDA-approved. Add calcium 1,200 mg daily, aerobic exercise, and cognitive behavioral therapy. GnRH agonist with add-back therapy is reserved for refractory disease.

Menstrual Toxic Shock Syndrome

Toxic shock syndrome (TSS) is caused by TSST-1–producing Staphylococcus aureus and, in its menstrual form, is associated with high-absorbency tampons and with diaphragms, cervical caps, contraceptive sponges, and menstrual cups left in place too long.

Recognize it by the constellation: fever ≥38.9 °C, diffuse macular erythroderma ("sunburn" rash), hypotension with systolic ≤90 mmHg, desquamation of the palms and soles 1 to 2 weeks later, and involvement of three or more organ systems (vomiting or diarrhea, myalgia with creatine kinase at least twice normal, mucous membrane hyperemia, renal or hepatic derangement, platelets below 100,000, or disorientation).

Counsel every menstruating patient: use the lowest absorbency that works, change tampons every 4 to 8 hours, alternate with pads especially overnight, do not exceed the recommended wear time for a cup, and never leave a diaphragm in longer than 24 hours. Wash hands before insertion and removal. A prior episode of TSS is a contraindication to tampons, cups, diaphragms, and cervical caps.